trending Market Intelligence /marketintelligence/en/news-insights/trending/levafvn72d9kko3j8nkpjq2 content esgSubNav
In This List

Fitch affirms Bio-Rad's rating; outlook stable

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


Fitch affirms Bio-Rad's rating; outlook stable

Fitch Ratings affirmed Bio-Rad Laboratories Inc.'s BBB- long-term issuer-default rating.

The outlook on the rating is stable.

The rating agency highlighted Bio-Rad's new long-term business strategy, unveiled in 2017, which involves seeking attractive acquisitions as well as a refocus on research and development spend. Fitch assumes EBITDA margin improvement, annual acquisitions and modest share repurchases under the new development plan.

Additionally, Fitch described the company as a value-based acquirer, conducting tuck-in purchases since 2012, but now with the possibility for transformational transactions.

In terms of leverage, Bio-Rad's conservative financial policy, lack of significant acquisitions and repayment of subordinated debt in 2013 have consistently kept its leverage below 2.3x, according to Fitch. However, the rating agency said Bio-Rad's historically low leverage may be temporary, given its new business strategy.

Moody's previously affirmed Bio-Rad's Baa3 senior unsecured rating, with a positive outlook.

Bio-Rad is a life sciences and diagnostics company based in in Hercules, Calif.